Try our Advanced Search for more refined results
Pfizer Inc et al. Inter Partes Review
Case Number:
Case Type:
IPR
Status:
Trial Instituted
Petitioner:
Pfizer Inc et al.
Patent Owner:
Tech Center:
-
March 20, 2024
PTAB To Analyze Moderna COVID Vaccine Patents
The Patent Trial and Appeal Board has agreed to review two Moderna COVID-19 vaccine patents challenged by rivals Pfizer and BioNTech as having "unimaginably broad claims directed to a basic idea that was known long before."
-
January 30, 2024
Pfizer Says Moderna Telling FDA One Thing, PTAB Another
Pfizer has told the Patent Trial and Appeal Board that the language Moderna used to quickly gain approval from the U.S. Food and Drug Administration for its COVID-19 vaccines should doom its efforts to defend its patents at the board, accusing it of pursuing a "litigation-driven one-eighty."
-
January 16, 2024
Pfizer Calls Moderna 'Willfully Naïve' In Covid Vax IP Fight
Pfizer and BioNTech have told the Patent Trial and Appeal Board not to rely on the timing of district court patent litigation to reject their challenges to a pair of Moderna COVID vaccine patents, arguing that the company relied on "cherry-picked data" and is acting "willfully naïve."
-
December 11, 2023
Moderna Says Pfizer COVID Vax Patent Challenges Fail Fintiv
Moderna has urged the Patent Trial and Appeal Board not to review its COVID-19 vaccine patents challenged by rivals Pfizer and BioNTech, saying a related district court trial will likely end before the board's decision is due, and the petitions don't show that the patents are invalid.